Associated Papers
A framework for the molecular identification of CHIP for clinical research.
Harraka P et al.
Hgg Advances, 2026
Prognostic significance of somatic mutations in myeloid cells of men with chronic heart failure - interaction between loss of Y chromosome and clonal haematopoiesis.
Cremer S et al.
European Journal of Heart Failure, 2025
Myeloid sarcoma shows a high frequency of mutations activating the MAPK/ERK pathway and association with clonal hematopoiesis.
Nann D et al.
The Journal of Pathology. Clinical Research, 2025
Integrating Molecular Alterations with Immunophenotype and Clinical Characteristics in Myelodysplastic Syndromes: A Single-Center Study.
Majcherek M et al.
International Journal of Molecular Sciences, 2025
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
Ikoma Y et al.
Leukemia, 2025
Multiomic profiling of human clonal hematopoiesis reveals genotype and cell-specific inflammatory pathway activation.
Heimlich JB et al.
Blood Advances, 2024
TP53 and KMT2D mutations associated with worse prognosis in peripheral T-cell lymphomas.
Wang L et al.
Cancer Medicine, 2024
Molecular genetic characterization of myeloid neoplasms with idic(X)(q13) and i(X)(q10).
Brunetti M et al.
Frontiers in Oncology, 2024
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
Johnson WT et al.
Blood Advances, 2023
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
McCarter JGW et al.
Blood Advances, 2023
Leukocytes carrying Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations invade Human Atherosclerotic Plaques.
von Scheidt M et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Nannya Y et al.
Blood Advances, 2023
Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms.
Hinze A et al.
British Journal of Haematology, 2023
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R et al.
Signal Transduction and Targeted Therapy, 2023
Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.
Stölzel F et al.
Jci Insight, 2023
Mutational Landscape of Patients Referred for Elevated Hemoglobin Level.
Bhai P et al.
Current Oncology (toronto, Ont.), 2022
The longitudinal dynamics and natural history of clonal haematopoiesis.
Fabre MA et al.
Nature, 2022
Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
Venable ER et al.
American Journal of Clinical Pathology, 2021
Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.
Pastoret C et al.
Blood, 2021
Improved Variant Detection in Clinical Myeloid NGS Testing by Supplementing a Commercial Myeloid NGS Assay with Custom or Extended Data Filtering and Accessory Fragment Analysis.
Schejbel L et al.
Molecular Diagnosis & Therapy, 2021
Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
Rosenthal SH et al.
Plos One, 2021
Integration of intra-sample contextual error modeling for improved detection of somatic mutations from deep sequencing.
Abelson S et al.
Science Advances, 2020
Strategy for identification of a potential inherited leukemia predisposition in a 299 patient's cohort with tumor-only sequencing data.
Aguilera-Diaz A et al.
Leukemia Research, 2020
Hematopoietic alterations in chronic heart failure patients by somatic mutations leading to clonal hematopoiesis.
Dorsheimer L et al.
Haematologica, 2020
TET2 missense variants in human neoplasia. A proposal of structural and functional classification.
Bussaglia E et al.
Molecular Genetics & Genomic Medicine, 2019
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.
Montalban-Bravo G et al.
Blood Advances, 2019
Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.
Stosch JM et al.
British Journal of Haematology, 2018
Prediction of acute myeloid leukaemia risk in healthy individuals.
Abelson S et al.
Nature, 2018
IL1RAP potentiates multiple oncogenic signaling pathways in AML.
Mitchell K et al.
The Journal of Experimental Medicine, 2018
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.
Wong TN et al.
Nature Communications, 2018
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.
Pawlyn C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S et al.
Leukemia, 2012